Is HUM a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Demographic tailwind in Medicare Advantage, with revenue (ttm) at ~$130 billion. The bear case rests on the medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure. Analysts covering it are spread from $195.00 to $502.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $195.00, -46.6% from the $364.87 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Demographic tailwind in Medicare Advantage. The US population aged 65 and older keeps growing, and a rising share of seniors choose Medicare Advantage over traditional Medicare. The most optimistic analyst target on HUM is $502.00, +37.6% from the $364.87 price. That figure is only reachable if this thesis works close to its best case.

The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure. Star ratings are a second lever, since a slip in ratings reduces CMS quality-bonus payments and can force benefit cuts that hurt retention; Humana's ratings softened heading into 2026. Medicare Advantage reimbursement and broader healthcare policy are set by the government and can change rate updates, risk-adjustment rules, or audit intensity. Finally, aggressive membership growth or repricing can pressure profitability or cause member attrition if benefits are trimmed too far. The most pessimistic published target is $195.00, -46.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Humana Inc.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Demographic tailwind in Medicare Advantage) stalling in the reported numbers rather than in the narrative, the risk above (the medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals and risk tolerance, and this is not advice. The bull case is the aging-population tailwind, Humana's Medicare Advantage scale, CenterWell, and a margin recovery toward roughly 3% by 2028. The bear case is that medical costs, softer star ratings, and reimbursement changes have already pressured earnings and could keep margins thin. Weigh both and your own situation.

Humana is a health insurer focused on government programs, especially Medicare Advantage, where it covers about 7.1 million members. It also serves Medicaid and military TRICARE members. Through its CenterWell arm it operates pharmacy, senior primary care, and home-health businesses, aiming to coordinate care and capture more of the healthcare dollar for its own members.

Yes. Humana pays a quarterly dividend of about $0.885 per share, which works out to roughly a 1.5% yield at a share price near $380 in mid-2026. The company has paid and generally raised its dividend for many consecutive years and also repurchases stock, though dividend policy can change with earnings and is set by the board.